Laboratory signs of aspirin response in haemodialysis patients

References

• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–266.
   PubMed Web of Science ®Google Scholar
• United States Renal Data Systems: Annual Data Report USRDS, Minneapolis, MN; 2006.
   Google Scholar
• Luke RG. Chronic renal failure – a vasculopathic state. N Engl J Med 1998;339:841–3.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60.
   PubMed Web of Science ®Google Scholar
• Grove EL, Kristensen SD. Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiol 2009;5:247–58.
   PubMedGoogle Scholar
• Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96: 781–8.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008;99:121–6.
   PubMed Web of Science ®Google Scholar
• von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate. Hamostaseologie 2007;27:155–60.
   PubMedGoogle Scholar
• Jámbor C, Weber CF, Gerhardt K, Dietrich W, Spannagl M, Heindl B, Zwissler B. Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin ınduced platelet dysfunction. Anesth Analg 2009;109: 25–31.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624–32.
   PubMed Web of Science ®Google Scholar
• Bloom A, Greaves M, Preston FE, Brown CB. Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol 1986;62: 143–9.
   PubMed Web of Science ®Google Scholar
• Muir AR, Patterson C, McMullin MF, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ıschaemic heart disease. Heart 2009;95: 1225–9.
   PubMed Web of Science ®Google Scholar
• Cheng X, Chen WH, Simon DI. Aspirin resistance or variable response or both? Am J Cardiol 2006;98(10A): 11N–7N.
   PubMedGoogle Scholar
• Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426–5.
   PubMed Web of Science ®Google Scholar
• Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract 2007;61:826–34.
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809–17.
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195–8.
   PubMed Web of Science ®Google Scholar
• Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis. Int J Cardiol 2008; 128:166–71.
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593–9.
   PubMed Web of Science ®Google Scholar
• Nainggolan L. ASCET: Aspirin Non-Responsiveness and Clopidogrel Endpoint Trial Single antiplatelet therapies compared in stable CAD. Presented at the American Heart Association Scientific Sessions, 13–17 November 2010; Chicago, IL.
   Google Scholar
• Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:1348–9.
   Web of Science ®Google Scholar
• Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26:3264–72.
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008;51:1829–43.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20.
   PubMed Web of Science ®Google Scholar